- Home
- QCRH vs EVO Comparison
QCRH vs EVO Comparison
Compare QCRH & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- EVO
- Stock Information
- Founded
- QCRH 1993
- EVO 1993
- Country
- QCRH United States
- EVO Germany
- Employees
- QCRH N/A
- EVO N/A
- Industry
- QCRH Major Banks
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- QCRH Finance
- EVO Health Care
- Exchange
- QCRH Nasdaq
- EVO Nasdaq
- Market Cap
- QCRH 1.3B
- EVO 1.2B
- IPO Year
- QCRH 1993
- EVO 2021
- Fundamental
- Price
- QCRH $79.25
- EVO $3.73
- Analyst Decision
- QCRH Buy
- EVO Buy
- Analyst Count
- QCRH 3
- EVO 2
- Target Price
- QCRH $88.83
- EVO $5.40
- AVG Volume (30 Days)
- QCRH 85.6K
- EVO 41.5K
- Earning Date
- QCRH 10-22-2025
- EVO 11-05-2025
- Dividend Yield
- QCRH 0.30%
- EVO N/A
- EPS Growth
- QCRH N/A
- EVO N/A
- EPS
- QCRH 6.63
- EVO N/A
- Revenue
- QCRH $322,873,000.00
- EVO $912,894,891.00
- Revenue This Year
- QCRH N/A
- EVO $0.39
- Revenue Next Year
- QCRH $14.12
- EVO $9.53
- P/E Ratio
- QCRH $11.89
- EVO N/A
- Revenue Growth
- QCRH N/A
- EVO N/A
- 52 Week Low
- QCRH $60.83
- EVO $2.84
- 52 Week High
- QCRH $96.08
- EVO $5.64
- Technical
- Relative Strength Index (RSI)
- QCRH 59.46
- EVO 57.04
- Support Level
- QCRH $76.54
- EVO $3.43
- Resistance Level
- QCRH $79.50
- EVO $3.55
- Average True Range (ATR)
- QCRH 1.83
- EVO 0.08
- MACD
- QCRH -0.22
- EVO 0.05
- Stochastic Oscillator
- QCRH 80.05
- EVO 90.27
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.